Vijay K. Kuchroo

Co-Founder at Celsius Therapeutics, Inc.

Vijay K. Kuchroo

Vijay K. Kuchroo

Co-Founder at Celsius Therapeutics, Inc.

Overview
Career Highlights

Celsius Therapeutics, Inc.
Tizona Therapeutics, Inc.
Costim Pharmaceuticals, Inc.

RelSci Relationships

1254

Number of Boards

6

Relationships
RelSci Relationships are individuals Vijay K. Kuchroo likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Tizona Therapeutics, Inc.

Relationship likelihood: Strong

Founder at Jounce Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Tizona Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Tizona Therapeutics, Inc.

Relationship likelihood: Strong

Founder at Biocon Ltd.

Relationship likelihood: Strong

Associate Professor of Neurology at Harvard University - Harvard Medical School

Relationship likelihood: Strong

Executive Partner at Mpm Capital LLC

Relationship likelihood: Strong

Lloyd J. Old-Virginia & Daniel K. Ludwig Chair in Clinical Investigation, Chief, Melanoma & Immunotherapeutics Service, Director, Parker Institute for Cancer Immunotherapy, Msk & Associate Director, Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Co-Founder at Celsius Therapeutics, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Director at Syngene International Ltd.

Relationship likelihood: Strong

Paths to Vijay K. Kuchroo
Potential Connections via
Relationship Science
You
Vijay K. Kuchroo
Co-Founder at Celsius Therapeutics, Inc.
Education

Brisbane, Qld, AUSTRALIA

Memberships
Associate Member

The Broad Institute evolved from a decade of informal and successful research collaborations among scientists in the MIT and Harvard communities. In 1990, the Whitehead Institute/MIT Center for Genome Research (WICGR) was founded, and it soon became an international leader in the field of genomics and a flagship of the Human Genome Project. As early as 1995, WICGR scientists recognized the need to bring the power of genomics to the understanding of human disease. It launched pilot projects in genomic medicine, forming an unofficial collaborative network among scientists from across MIT and Harvard who pioneered new approaches to cancer and human genetics. In parallel, Harvard Medical School-based scientists established the Institute of Chemistry and Cell Biology (ICCB) in 1998, to facilitate the pursuit of chemical genetics as an academic discipline and a tool to further understand human biology and disease. In 2002, the ICCB was awarded an Initiative for Chemical Genetics (ICG) grant from the National Cancer Institute, and its successful Investigator-Initiated Screening Program facilitated small molecule screening projects for more than 80 research groups worldwide. These projects demonstrated the power of enabling scientists to collaborate to tackle the major challenges in molecular medicine. It was clear that a new type of formal organization was required — open, collaborative, interdisciplinary, and able to organize projects at any scale. In addition, it was important that the complementary expertise of the genomic scientists and the chemical biologists across MIT and Harvard be brought together in one place to drive the transformation of medicine with molecular knowledge. Discussions in 2002-2003 among Eli and Edythe Broad, MIT, Harvard and its affiliated hospitals, and the Whitehead Institute shaped the vision for this new institute. The extraordinary generosity of Eli and Edythe Broad, through their founding gift of $100 million (later doubled to $200 million) made it possible to formally announce the new institute in June 2003 and to launch it in May 2004. Less than four years after its launch, the Broads gave an unprecedented gift of $400 million in September 2008 to permanently endow the institute, providing long-term sustainability for its unique model of collaborative, inter-institutional research.

Career History
Co-Founder
2018 - Current

Celsius Therapeutics, Inc. translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer. The company was founded by Jeffrey A. Bluestone, Vijay K. Kuchroo, Christoph S. Lengauer, Aviv Regev and Ramnik Xavier in 2018 and is headquartered in Boston, MA.

Co-Founder
Current

Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew Pardoll, Dario Vignali, and Jedd Wolchok and is headquartered in South San Francisco, CA.

Professor
Current

Harvard Medical School (HMS) is the graduate medical school of Harvard University. It is located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts.The school was founded by John Warren on September 19, 1782, with Benjamin Waterhouse, and Aaron Dexter.

Boards & Committees
Member, Scientific Advisory Board
Current

Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA.

Investments
Details Hidden

Celsius Therapeutics, Inc. translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer. The company was founded by Jeffrey A. Bluestone, Vijay K. Kuchroo, Christoph S. Lengauer, Aviv Regev and Ramnik Xavier in 2018 and is headquartered in Boston, MA.

Details Hidden

Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew Pardoll, Dario Vignali, and Jedd Wolchok and is headquartered in South San Francisco, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Vijay K. Kuchroo. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Vijay K. Kuchroo's profile does not indicate a business or promotional relationship of any kind between RelSci and Vijay K. Kuchroo.